Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02843659 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02843659 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 45 participants.
The verdict
NCT02843659, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from baseline in ESSDAI at Week 12 between active treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.
Interventions
- DRUG Placebo
- DRUG BMS-986142
- DRUG BMS-931699
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2016-10-18 |
| Est. Completion | 2017-07-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02843659
The ClinicalTrials.gov registry entry for NCT02843659 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02843659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02843659 about?
NCT02843659 is a clinical study titled "Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome". The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from baseline in ESSDAI at Week 12 between active treatment arms (lulizumab or BMS-...
What is the current status of trial NCT02843659?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2016-10-18. Estimated completion is 2017-07-24.
What interventions are being tested in trial NCT02843659?
The interventions under investigation include: Placebo (DRUG), BMS-986142 (DRUG), BMS-931699 (DRUG).
Who is sponsoring clinical trial NCT02843659?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.